modafinil (armodafinil)

Subscribe to Selected New Research on modafinil

383 relevant articles (91 outcomes, 110 trials/studies) found for this Drug

Description: metabolite of adrafinyl; armodafinil is the (R)-isomer

Also Known As:

armodafinil; Provigil; Alertec; Modiodal; Nuvigil; CEPA brand of modafinil; CRL 40476; CRL-40476; Cephalon brand of armodafinil; Cephalon brand of modafinil; Cephalon brand of modafinil, reformulated; Draxis brand of modafinil; Lafon brand of modafinil; Merckle brand of modafinil; Nourypharma brand of modafinil; Sparlon; Vigil; benzhydrylsulfinylacetamide

Relationship Network

Drug Context: Research Results

Organic Chemicals: 42

Hydrocarbons: 362

Cyclic Hydrocarbons: 3

Aromatic Hydrocarbons: 121

Benzene Derivatives: 9

Benzhydryl Compounds

modafinil: 383

Experts

1.	Arora, Sanjay: 7 articles (03/2008 - 08/2005)
2.	Biederman, Joseph: 6 articles (03/2008 - 12/2005)
3.	Hughes, Rod J: 6 articles (07/2007 - 09/2003)
4.	Schwartz, Jonathan R L: 6 articles (08/2005 - 09/2003)
5.	Balkin, Thomas J: 5 articles (09/2008 - 01/2002)
6.	Earl, Craig Q: 5 articles (12/2006 - 12/2005)
7.	Swanson, James M: 5 articles (05/2006 - 12/2005)
8.	Killgore, William D S: 4 articles (09/2008 - 09/2005)
9.	Sahakian, Barbara J: 4 articles (07/2008 - 05/2004)
10.	Roth, Thomas: 4 articles (03/2008 - 08/2005)

Related Diseases

1.	Fatigue 06/01/1997 - "Although modafinil has proven to be a safe and effective countermeasure to the effects of extensive SD on cognitive task performance, we encourage a more comprehensive understanding of the relation between its subjective and performance enhancing effects before the drug is recommended as a viable fatigue countermeasure." 07/01/2007 - "RESULTS: Compared to placebo, modafinil augmentation rapidly (within 1 week) and significantly improved overall clinical condition (Clinical Global Impression-Improvement), wakefulness (ESS), depressive symptoms (17-item HAM-D), and fatigue (FSS) (p<.01 for all). " 03/01/2007 - "Armodafinil significantly improved episodic secondary memory (P=0.0102) and patient-estimated wakefulness (P<0.01) and reduced fatigue (P<0.05) compared with placebo. " 04/01/2006 - "Armodafinil also significantly improved overall clinical condition, memory, attention, and fatigue when compared with placebo." 07/01/2005 - "In the modafinil (N = 10) and placebo (N = 10) groups, fatigue improved significantly over time (p < .01), but there were no differences between groups on changes in fatigue, positive and negative symptoms, or cognition. " Order ALL the reference details at left...
2.	Narcolepsy 01/01/2005 - "The clinical efficacy of modafinil, combined with improved safety over CNS stimulants, has made it the most prescribed medication for the treatment of ES associated with narcolepsy. " 09/01/2009 - "Compared with placebo, mean sleep latency (coprimary endpoint) was significantly improved with armodafinil 150 or 250 mg once daily in patients with OSA or narcolepsy, and with armodafinil 150 mg once daily in patients with SWSD, as assessed by the Multiple Sleep Latency Test (MSLT) or the Maintenance of Wakefulness Test (MWT). " 01/15/2007 - "In conclusion, modafinil did not influence thymopsychic variables in narcolepsy, but it significantly improved cognitive performance, which may be related to medial prefrontal activity processes identified by LORETA." 04/01/2006 - "CONCLUSIONS: Armodafinil significantly improved ability to sustain wakefulness throughout the day in patients with narcolepsy. " 06/01/1998 - "Modafinil is an alerting substance which has been used successfully to treat narcolepsy. " Order ALL the reference details at left...
3.	Disorders of Excessive Somnolence (Hypersomnia) 12/01/2007 - "However, the hypersomnia items on the 31-item Hamilton Depression Scale were significantly more improved with modafinil than placebo. " 12/01/2003 - "The addition of the selective psychostimulant modafinil resulted in significant improvement in the hypersomnia, with improvement in functioning. " 08/01/2009 - "OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of modafinil for the treatment of hypersomnia in adults with MMD1. " 01/01/2005 - "Modafinil in doses of 100-400 mg was administered as augmentation to ongoing antidepressant therapy in patients with partial response and suffering from hypersomnia. " 01/01/2005 - "Modafinil, an atypical wakefulness-promoting agent with an unknown mechanism of action, is used to treat hypersomnolence in these patients. " Order ALL the reference details at left...
4.	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 03/01/2008 - "OBJECTIVE: This secondary analysis evaluated the efficacy of modafinil in children and adolescents by subtype of attention-deficit/hyperactivity disorder (ADHD) using pooled data from 3 double-blind, placebo-controlled studies. " 12/01/2006 - "OBJECTIVE: In a 4-week, double-blind, placebo-controlled study, the attention-promoting agent modafinil improved symptoms of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents and was well tolerated. " 08/01/2003 - "The average Test of Variables of Attention attention-deficit hyperactivity disorder z score improved by 2.53 S.D.s for the modafinil group compared with a decline of 1.02 for control patients (P < or = 0.02). " 12/01/2006 - "Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study." 05/01/2006 - "OBJECTIVE: This randomized, double-blind, placebo-controlled study assessed the efficacy and tolerability of several modafinil dosing regimens in children with attention-deficit/hyperactivity disorder (ADHD) to determine whether modafinil can be given once daily in pediatric ADHD. " Order ALL the reference details at left...
5.	Parkinson Disease (Parkinson's Disease) 12/01/2002 - "OBJECTIVES: To assess the therapeutic efficacy of modafinil in the treatment of increased daytime sleepiness in patients with Parkinson's disease (PD). " 03/01/2003 - "We assessed the safety and efficacy of modafinil for the treatment of excessive daytime sleepiness in patients with Parkinson's disease (PD). " 12/01/2005 - "Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial." 03/01/2003 - "Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease." 12/01/2002 - "Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial." Order ALL the reference details at left...

Related Drugs and Biologics

1.	modafinil (armodafinil)
2.	Sodium Oxybate (gamma Hydroxybutyrate)
3.	Dextroamphetamine (Dexedrine)
4.	Methylphenidate (Ritalin)
5.	Amantadine (Aman)
6.	Amphetamine (Amfetamine)
7.	Caffeine (No Doz)
8.	Serotonin (5 Hydroxytryptamine)
9.	Antidepressive Agents (Antidepressants)
10.	Cocaine (Cocaine HCl)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Activities of Daily Living (ADL)
3.	Continuous Positive Airway Pressure
4.	Drug Therapy (Chemotherapy)
5.	Self Administration (Administration, Self)

Best Treatments:
Research Summary Report
on Fatigue

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 574 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>